Cancer News: Myeloma
European regulators have adopted a positive opinion for ixazomib capsules combined with lenalidomide and dexamethasone for the treatment of multiple myeloma.
Researchers discovered that the patient’s body mass index is contributing to multiple myeloma growth and progression.
EU regulator approved carfilzomib with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy.
Adding daratumumab to a standard two-drug regimen reduced the risk of cancer progression in patients with recurrent or refractory multiple myeloma.
European regulators have recommended conditional approval for daratumumab, an immunotherapy treatment for multiple myeloma.
A new immunotherapy-related therapeutic approach against multiple myeloma induced record-level clinical results, researchers reveal.
Adding carfilzomib to the treatment of relapsed and/or refractory multiple myeloma with bortezomib and lenalidomide induced positive results, a new study shows.
Multiple myeloma patients treated with daratumumab combined with standard chemotherapy lived longer without disease progression, a new study finds.
Clinical results reveal the effectiveness of ixazomib plus lenalidomide and dexamethasone in treating patients with relapsed and/or refractory multiple myeloma.
Relapsed multiple myeloma patients treated with carfilzomib plus dexamethasone instead of bortezomib plus dexamethasone lived twice as long without disease progression.
The monoclonal antibody, Elotuzumab, received FDA’s approval to be used for the treatment of myeloma in combination with lenalidomide (Revlimid) and dexamethasone.
The FDA approved the immuno-oncology treatment, Empliciti, for the treatment of patients with multiple myeloma.
European regulators approved carfilzomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma.
Takeda’s oral myeloma treatment, ixazomib (Ninlaro), got approved by the FDA as a second-line combination therapy.
The FDA approved Johnson & Johnson’s immunotherapy drug, Darzalex (daratumumab) for the treatment of patients with advanced multiple myeloma.
Daratumumab, a breakthrough antibody therapy, showed very promising results in drug-resistant patients with multiple myeloma whose disease had relapsed.
European regulators have accepted the marketing authorization application for ixazomib, an investigational oral drug meant to treat relapsed/refractory myeloma patients.
Researchers have discovered a method to identify which myeloma patients are at a greater risk of relapse and premature death.
European regulators have granted an accelerated assessment to Takeda’s ixazomib, a new drug for relapsed and/or refractory multiple myeloma.
Adding elotuzumab to standard treatment benefited patients with relapsed and refractory myeloma as it improved progression-free survival rates, a new study reveals.
Adding the innovative immunotherapy elotuzumab to standard treatment extended the duration of remissions by about five months in patients with relapsed multiple myeloma.
Novartis multiple myeloma drug, Farydak received FDA’s approval, in spite of advisory panel’s negative opinion.
Revlimid, already approved as a treatment for previously treated patients of multiple myeloma, will be available for newly diagnosed patients as well.
Investigators have produced significantly improved results for treating multiple myeloma by adding a 3rd drug to the accepted 2-drug combination in a trial.
The US FDA approved bortezomib for the re-treatment of multiple myeloma adult patients who relapsed at least six months after responding to bortezomib therapy.
Newer targeted therapies and genomic analysis are moving the management of relapsed/refractory multiple myeloma forward.
An experimental drug from Novartis to treat a type of bone marrow cancer met its primary goal in a late-stage study, the Swiss drugmaker said.
A continuous, combined treatment of multiple myeloma outperformed standard care in older patients or those not eligible for stem cell transplant, according to a researcher at the annual meeting of the American Society of Hematology.
Most newly diagnosed multiple myeloma patients had a very strong response to an experimental oral drug, when given in combination with standard treatments, according to a trial.
Multiple myeloma patients in remission after initial therapy can prolong the time to relapse through lenalidomide (Revlimid) maintenance treatment (an immune modulator).